Xenon Pharmaceuticals Stock Forecast, Price & News

Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

Is Xenon Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Xenon Pharmaceuticals stock.
View analyst ratings for Xenon Pharmaceuticals or view top-rated stocks.

How has Xenon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Xenon Pharmaceuticals' stock was trading at $12.71 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XENE shares have increased by 103.2% and is now trading at $25.83.
View which stocks have been most impacted by COVID-19.

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Xenon Pharmaceuticals.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.44) by $0.08. Xenon Pharmaceuticals had a negative trailing twelve-month return on equity of 28.30% and a negative net margin of 328.86%. During the same period in the previous year, the business posted ($0.25) EPS.
View Xenon Pharmaceuticals' earnings history.

What price target have analysts set for XENE?

5 equities research analysts have issued 1-year price objectives for Xenon Pharmaceuticals' shares. Their forecasts range from $40.00 to $48.00. On average, they expect Xenon Pharmaceuticals' share price to reach $44.00 in the next year. This suggests a possible upside of 70.3% from the stock's current price.
View analysts' price targets for Xenon Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the following people:

• Ian C. Mortimer, President, Chief Executive Officer & Director
• Sherry Aulin, Chief Financial Officer
• Sheila M. Grant, Senior VP-Research & Development Operations
• Christopher Kenney, Chief Medical Officer
• Robin Sherrington, Executive Vice President-Strategy & Innovation

Who are some of Xenon Pharmaceuticals' key competitors?

Some companies that are related to Xenon Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), Mawson Infrastructure Group (WIZP), Perrigo (PRGO), I-Mab (IMAB), Cerevel Therapeutics (CERE), Allakos (ALLK), Arvinas (ARVN), Apellis Pharmaceuticals (APLS), Karuna Therapeutics (KRTX), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Zentalis Pharmaceuticals (ZNTL), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA) and Galapagos (GLPG).
View all of XENE's competitors.

What other stocks do shareholders of Xenon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI).

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Suvretta Capital Management LLC (2.25%), Point72 Asset Management L.P. (2.62%), Bank of New York Mellon Corp (1.81%), Great Point Partners LLC (1.70%), Renaissance Technologies LLC (1.51%) and Rock Springs Capital Management LP (1.42%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends for Xenon Pharmaceuticals.

Which major investors are selling Xenon Pharmaceuticals stock?

XENE stock was sold by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, Goldman Sachs Group Inc., Knott David M, Renaissance Technologies LLC, Morgan Stanley, Lord Abbett & CO. LLC, Scotia Capital Inc., and Shell Asset Management Co.. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, Sherrington Robin, and Simon N Pimstone.
View insider buying and selling activity for Xenon Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Xenon Pharmaceuticals stock?

XENE stock was purchased by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Suvretta Capital Management LLC, Caption Management LLC, Tri Locum Partners LP, Commodore Capital LP, Alliancebernstein L.P., Monashee Investment Management LLC, and Point72 Asset Management L.P..
View insider buying and selling activity for Xenon Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $25.83.

How much money does Xenon Pharmaceuticals make?

Xenon Pharmaceuticals has a market capitalization of $1.33 billion and generates $32.17 million in revenue each year. The biopharmaceutical company earns $-28.84 million in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Xenon Pharmaceuticals have?

Xenon Pharmaceuticals employs 129 workers across the globe.

What is Xenon Pharmaceuticals' official website?

The official website for Xenon Pharmaceuticals is www.xenon-pharma.com.

Where are Xenon Pharmaceuticals' headquarters?

Xenon Pharmaceuticals is headquartered at 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at [email protected], or via fax at 604-484-3450.